BARCELONA, Spain — In the phase 2 ARCHER trial, ANX007, a novel C1q inhibitor with neuroprotective properties, showed consistent protection against loss of visual acuity in eyes with geographic atrophy.
One-year study results as well as 18-month extension data were presented by Usha Chakravarthy, MD, PhD, at the Euretina congress.
ANX007 (Annexon Biosciences) was administered intravitreally every month or every other month and compared with a sham injection.
“The primary outcome was the change in GA area measured by fundus autofluorescence, but there were key secondary outcomes that